None listed
Conditions
Brief summary
Obstructive sleep apnoea (OSA) is a condition in which the upper airway collapses during sleep, leading to episodes of sleep fragmentation and hypoxemia. OSA has been linked to a decrease in neurocognitive function in some patients and potentially to the development of dementia, however the mechanisms remain unclear. This clinical study will investigate the link(s) between cerebrovascular response to hypoxemia, arterial stiffness, brain tissue hypoxia and neurocognitive function in OSA patients, before and after 8 weeks of CPAP treatment.
Interventions
Continuous positive airway pressure (CPAP)
This is routine gold-standard treatment.
Participants will have an in-lab CPAP titration study with pressure adjustment by trained sleep technologist. The delivered pressure will be determined by the CPAP titration study. Mask fitting and CPAP education will also be provided by trained sleep technologist. A loan CPAP machine (Resmed S8 or Phillips REMSTAR) will be provided on loan for participant use.
After starting therapy, the participant will be a
Continuous positive airway pressure (CPAP) This is routine gold-standard treatment. Participants will have an in-lab CPAP titration study with pressure adjustment by trained sleep technologist. The delivered pressure will be determined by the CPAP titration study. Mask fitting and CPAP education will also be provided by trained sleep technologist. A loan CPAP machine (Resmed S8 or Phillips REMSTAR) will be provided on loan for participant use. After starting therapy, the participant will be asked to return at 2 weeks for a device download and any required trouble shooting as well as at 6 weeks if required. Participants will use their CPAP machine for a total of 3 months treatment period prior to re-testing. The CPAP machine data will be recorded at 2 weeks and end of 3 months therapy. This will include data on CPAP adherence throughout the 3 months period.
Sponsors
Craig Phillips
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
• PSG confirmed ODI >/= 15 and AHI >/= 30 with a diagnosis of moderate-severe hypoxemic OSA; • Recommended for CPAP treatment by the attending sleep physician • Ability to perform neurobehavioral tests; • Able to give informed consent; • Fluent in English.
Exclusion criteria
• Clinically significant co-morbidity; • History of head injury or psychiatric/neurological disorder (including stroke); • Use of CNS active agents; • Heavy alcohol consumption (40g daily); • Current shift-worker or travelled overseas within the last 2 weeks; • Previously used CPAP; • Excessive symptoms and/or very severe OSA which in the opinion of the treating physician requires urgent CPAP treatment
Outcome results
None listed